Hexagon Nutrition Limited IPO - Should you apply?

Key Takeaways:

The IPO will be open for subscription from June 5, 2026, to June 9, 2026.
The IPO is a book-built issue of Rs. 138.87 crore with a tentative listing on June 12, 2026.
The issue is priced in the price band of Rs 42 to Rs 45 per share.
The issue is OFS only. No new equity shares would be issued.
Profit After Tax and Total Income are Rs 24.38 crore and Rs 331.29 crore in FY 25, respectively.

In June 2026, the recent entrant to India's primary market is Hexagon Nutrition Limited's IPO from the health and wellness space. The subscription will be open from June 5, 2026, to June 9, 2026. The issue is an offer of Rs. 138.87 crore, which is a pure Offer for Sale (OFS) from the existing shareholders. In the offer, 3.09 crore equity shares are being offloaded by the stakeholders at a price band of Rs 42 to Rs 45.

The lot size is 333 shares, and the retail investors will have to invest Rs 14,985 to apply for a minimum of one lot of shares. Allotment of the IPO is expected on June 10, 2026, and the listing is tentatively scheduled on June 12, 2026, on both the NSE and BSE.

Hexagon Nutrition Limited company details

Hexagon Nutrition Limited was incorporated in 1993 and, since then, has grown as a nutrition company with an R&D focus. The company, which is based in Mumbai, develops and manufactures various products like micronutrient premixes, branded wellness and clinical nutrition, therapeutic formulation, and ready-to-use foods.

Its product portfolio can be segmented under the three main business categories:

Branded wellness and clinical nutrition products (B2C)
Premix formulations (B2B2C)
Ready-to-Use foods (RUF) and Micronutrient Powders (MNP) under the ESG initiative

The company owns 4 manufacturing facilities, 3 in India at Nashik, Chennai, and Thoothukudi, and one in Tashkent, Uzbekistan. Two of its Indian facilities at Chennai and Thoothukudi are in Special Economic Zones, providing perks like strategic logistics and duty-free imports, in addition to its R&D facility in Nashik and Chennai.

The financial performance of the company also shows an upward trajectory. The Total Income and Profit After Tax for the company have increased from Rs 281.65 crore and Rs 5.82 crore in FY 23 to Rs 331.29 crore and Rs 24.38 crore in FY 25, respectively. The rise in profitability is due to higher margins and increased exports, which account for over 61% of its total income, and exports are made to more than 75 countries across the globe.

Should you invest in the IPO?

To understand whether to apply for this IPO, it is necessary for investors to thoroughly gauge the company's pros and cons. Let’s understand them in detail:

Pros of investing in the Hexagon Nutrition Limited IPO:

Integrated operations with strong R&D: Hexagon controls the entire value chain from research and development to production and distribution, with two dedicated R&D centres. Additionally, it has the capability to develop customised formulations without compromising taste or texture.
Market leadership in micronutrient premixes: The company is a leading player in the Indian customised vitamin and mineral premix market and is a trusted distributor for many major FMCG brands. It's also one of the largest licensed suppliers of Micronutrient Powders (MNPs) to UN programs.
Established wellness brand portfolio: Hexagon has developed a strong portfolio of recognised clinical wellness brands, including PENTASURE, PEDIAGOLD, and OBESIGO. These products have higher margins, have gained regulatory approval in over 14 countries, and have sticky customer bases.
Long-standing relationships with customers: The company has built and maintained strong relationships with customers across B2C, B2B2C, and ESG segments. It was achieved through their product quality, reliability, and ability to meet different nutritional needs around the world.
Global reach: They export to more than 75 countries and have manufacturing plants in SEZs, which provide them with strategic logistics and duty-free import advantages.

Cons of investing in the Hexagon Nutrition Limited IPO:

Customer concentration risk: Its top 10 clients account for a substantial proportion of the company’s overall revenues. Loss or dilution of the business with any top client would have a detrimental impact on its business.
Volatility in raw material prices: The business is largely dependent on raw materials for producing vitamins, minerals, and food-grade ingredients; the price volatility of raw materials, coupled with the absence of fixed-price long-term contracts, can have a significant impact on its margins.
Strict quality and liability risks: The clinical nutrition market is highly regulated. Any failure to meet these standards can lead to brand damage, product recalls, and legal liabilities.
Geographical concentration of manufacturing: The company has manufacturing units at Nashik, Chennai, & Thoothukudi. Any of these units being adversely affected by events like natural calamity, labour strike, fire, etc., would cease its operation altogether.
Foreign exchange fluctuations: As a part of the revenues is derived from exports, and raw materials are imported, it is susceptible to exchange rate fluctuations that may reduce its net profit realisations.

Conclusion

Hexagon Nutrition Limited IPO gives investors an attractive opportunity to invest in a niche, research-driven business in the quickly growing segment of clinical nutrition and food fortification. The company's strong R&D facilities, having its own manufacturing units, robust institutional relations with the UN agencies, and healthy PAT growth to Rs 24.38 crore as of FY25 indicate strong factors driving the investors' interest in this IPO.

However, its IPO's 100% OFS structure is a major headwind as no IPO proceeds will be injected into the company to drive future growth. Also, the high dependence of the company on imported raw materials and high export concentration make its business highly sensitive to global macroeconomic changes and currency risks.

The issue appears fully priced at the price of Rs 42-45, considering the financial growth trajectory of the company in recent years. This issue is an attractive investment option for investors who have a medium to long-term investment horizon and understand the structural tailwinds of the global wellness and preventive healthcare market.